Home  |  Contact

Cellosaurus Kasumi-1 (CVCL_0589)

[Text version]

Cell line name Kasumi-1
Synonyms KASUMI-1; Kasumi 1; KASUMI1; Kasumi1
Accession CVCL_0589
Resource Identification Initiative To cite this cell line use: Kasumi-1 (RRID:CVCL_0589)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Characteristics: Has lost chromosome Y (PubMed=2018839). But some chromosome Y fragments are integrated into other chromosomes (PubMed=18292219).
Doubling time: 40-45 hours (PubMed=2018839); 40 hours (PubMed=25984343); 53 hours (PubMed=20922763); ~48-72 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: Kusami-1; In Cosmic 1516633 and Cosmic 1623636.
Misspelling: KUSAMI-1; In Cosmic 2306211.
Derived from sampling site: Peripheral blood.
Sequence variations RUNX1-RUNX1T1 (AML1-ETO) gene fusion (PubMed=11753612; PubMed=15843827; PubMed=24976338; PubMed=25485619).
Heterozygous for KIT p.Asn822Lys (c.2466T>A) (PubMed=12111653; PubMed=18385756).
RAD21 p.Lys330Profs*6 (c.987insCCGG) (PubMed=23955599).
Homozygous for TP53 p.Arg248Gln (c.743G>A) (Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.19
Native American0
East Asian, North74.84
East Asian, South22.29
South Asian0
European, North0
European, South1.67
Disease Childhood acute myeloid leukemia with maturation (NCIt: C9381)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_JY44 (Kasumi-1 R48)
Sex of cell Male
Age at sampling 7Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; JCRB; PubMed=20922763; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,12
D2S133819
D3S135815,17
D5S8189,11
D7S8208,11
D8S117913,14
D13S31711,13
D16S5399,12
D18S5115,16
D19S43313,15.2
D21S1130,31
FGA22,24
Penta D12
Penta E11
TH016,9
TPOX8,9
vWA14 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; PubMed=20922763; PubMed=25877200)
14,18 (COG)

Run an STR similarity search on this cell line
Web pages http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=1709
http://www.cellresource.cn/fdetail.aspx?id=1973
Publications

PubMed=2018839
Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N.
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation.
Blood 77:2031-2036(1991)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11753612; DOI=10.1038/sj.leu.2402318
Xiao Z., Greaves M.F., Buffler P., Smith M.T., Segal M.R., Dicks B.M., Wiencke J.K., Wiemels J.L.
Molecular characterization of genomic AML1-ETO fusions in childhood leukemia.
Leukemia 15:1906-1913(2001)

PubMed=12111653; DOI=10.1038/sj.thj.6200168
Beghini A., Magnani I., Ripamonti C.B., Larizza L.
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.
Hematol. J. 3:157-163(2002)

PubMed=15621809; DOI=10.1080/10428190400007565
Larizza L., Magnani I., Beghini A.
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Leuk. Lymphoma 46:247-255(2005)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=18292219; DOI=10.1101/gr.068304.107
Chen J., Kim Y.C., Jung Y.-C., Xuan Z., Dworkin G., Zhang Y., Zhang M.Q., Wang S.M.
Scanning the human genome at kilobase resolution.
Genome Res. 18:751-762(2008)

PubMed=18385756; DOI=10.1038/leu.2008.61
Becker H., Pfeifer D., Afonso J.D., Nimer S.D., Veelken H., Schwabe M., Lubbert M.
Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.
Leukemia 22:1792-1794(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23955599; DOI=10.1038/ng.2731
Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S., Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D., Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K., Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Nakamaki T., Ishiyama K., Nolte F., Hofmann W.K., Miyawaki S., Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H., Haferlach T., Shirahige K., Miyano S., Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat. Genet. 45:1232-1237(2013)

PubMed=24211243; DOI=10.1016/j.exphem.2013.10.006
Herrmann M.D., Lennerz J.K., Bullinger L., Bartholomae S., Holzmann K., Westhoff M.-A., Corbacioglu S., Debatin K.-M.
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Exp. Hematol. 42:90-100(2014)

PubMed=24976338; DOI=10.1016/j.leukres.2014.06.002
Migas A.A., Mishkova O.A., Ramanouskaya T.V., Ilyushonak I.M., Aleinikova O.V., Grinev V.V.
RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells.
Leuk. Res. 38:1102-1110(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cross-references
Cell line collections ATCC; CRL-2724
BCRC; 60505
BCRJ; 0305
CCTCC; GDC0296
CLS; 300226/p633_Kasumi-1
DSMZ; ACC-220
IZSLER; BS TCL 242
JCRB; JCRB1003
JCRB; NIHS0235 - Discontinued
Cell line databases/resources CLDB; cl2998
CCLE; KASUMI1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3131C0001000700202
CCRID; 3142C0001000000322
Cell_Model_Passport; SIDM01005
Cosmic-CLP; 907275
DepMap; ACH-000263
GDSC; 907275
LINCS_LDP; LCL-1055
Ontologies BTO; BTO:0004136
CLO; CLO_0007068
CLO; CLO_0007069
EFO; EFO_0006607
MCCL; MCC:0000264
Biological sample resources BioSample; SAMN01821572
BioSample; SAMN01821642
BioSample; SAMN01821688
BioSample; SAMN03473161
BioSample; SAMN10988020
Chemistry resources ChEMBL-Cells; CHEMBL3307835
ChEMBL-Targets; CHEMBL613988
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM236785
GEO; GSM236821
GEO; GSM482490
GEO; GSM506744
GEO; GSM506867
GEO; GSM506973
GEO; GSM887197
GEO; GSM888270
GEO; GSM955189
GEO; GSM955190
GEO; GSM955191
GEO; GSM1374590
GEO; GSM1446745
GEO; GSM1669979
Other Wikidata; Q38098914
Polymorphism and mutation databases Cosmic; 787441
Cosmic; 907275
Cosmic; 975258
Cosmic; 981579
Cosmic; 987968
Cosmic; 1012076
Cosmic; 1078725
Cosmic; 1149336
Cosmic; 1181600
Cosmic; 1451847
Cosmic; 1476423
Cosmic; 1509202
Cosmic; 1516633
Cosmic; 1524831
Cosmic; 1623636
Cosmic; 1779131
Cosmic; 2089650
Cosmic; 2131540
Cosmic; 2306211
Cosmic; 2690663
Cosmic; 2701742
IARC_TP53; 21428
LiGeA; CCLE_291
Proteomic databases PRIDE; PXD000185
Entry history
Entry creation04-Apr-2012
Last entry updated05-Jul-2019
Version number31